Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Dronabinol FDA-Approved for Sleep Apnoea? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The question of whether dronabinol and FDA for sleep apnoea  has been formally recognised is important for patients seeking alternative therapies. Dronabinol is a synthetic form of THC studied for its potential to reduce airway collapse and improve breathing during sleep. While research shows some promise, full regulatory approval for OSA has not been granted. 

Am I eligible for medical cannabis for pain relief?

Current Status of Approval 

Although trials suggest benefits, dronabinol and FDA for sleep apnoea have not yet received official clearance. Patients considering this option should understand its current legal and medical standing. 

Research Findings 

Studies highlight that dronabinol and FDA for sleep apnoea trials have reduced apnoea events, but more evidence is needed. 

Regulatory Pathway 

The lack of complete regulatory approval for OSA means dronabinol remains under investigation rather than being a standard therapy. 

Clinical Use 

Doctors may discuss its potential, but decisions must align with cannabis legality for treatment policies in each region. 

Patient Awareness 

Those exploring treatment should know that approval status may differ between jurisdictions and could change with future studies. 

At present, dronabinol and FDA for sleep apnoea is not fully approved. While research offers hope, patients must rely on current legal guidelines and professional advice before considering it as part of their treatment plan. 

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories